Nanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation
Advanced Science · 2025
DOI: 10.1002/advs.202504252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yinfei Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. Hauptthemen laut MEDLINE: Immunity, Innate, Radioimmunotherapy, Interleukins, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
The cGAS‐STING signaling pathway has emerged as a promising target for cancer immunotherapy. However, STING agonists have a dual‐edged nature. Although they enhance antitumor T cell activity, STING agonists also elicit protumorigenic effects by promoting IL‐35‐producing B regulatory (Breg) cells, suppressing natural killer (NK) cell density, and fostering immune suppression. To address these challenges, this work develops a tumor microenvironment‐responsive hollow mesoporous nanosystem that degrades under high glutathione conditions, thereby releasing the STING agonist MSA‐2 and Mn ions. This nanosystem facilitates magnetic resonance imaging‐guided chemodynamic therapy and radiosensitization, efficiently activating the cGAS‐STING pathway by disrupting mitochondrial and nuclear DNA. Notably, by integrating this nanosystem with an anti‐IL‐35 blockade, this work successfully mitigates the Breg cell‐mediated suppression of NK cells, restores innate immune responses, and enhances antitumor efficacy. This study highlights the pivotal role of anti‐IL‐35 in reversing immunosuppression, enhancing innate immunity, and establishing a synergistic theranostic platform for molecular imaging‐guided cancer radioimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
- Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
- Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
- School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
- Experimental Education/Administration Center, School of Basic Medical Science, Southern Medical University, Guangzhou, 510515, China.
ORCID-Profile: Bingxia Zhao
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Zheng, Y., Zheng, S., Liao, Y., Wu, Z., He, C., Li, Q., Hu, H., Shen, Z., Xu, Y., Yan, C., Zhao, B., & Hou, M. (2025). Nanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation. Advanced Science. https://doi.org/10.1002/advs.202504252
Vancouver
Zheng Y, Zheng S, Liao Y, Wu Z, He C, Li Q, et al. Nanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation. Advanced Science. 2025. doi:10.1002/advs.202504252
BibTeX
@article{Zheng2025,
author = {Zheng, Yinfei and Zheng, Shuting and Liao, Yushu and Wu, Zede and He, Chenxi and Li, Qiuyu and Hu, Honglei and Shen, Zheyu and Xu, Yikai and Yan, Chenggong and Zhao, Bingxia and Hou, Meirong},
title = {Nanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504252}
}
EUVIMED